Klinische Bedeutung der mit klassischen und atypischen Neuroleptika induzierten Hyperprolaktinämie

L. Hermle; A. Bönsch; M. Ruchsow

doi:10.1055/s-0038-1626880

Nervenheilkunde, Table of Contents

Nervenheilkunde 2007; 26(05): 417-419
DOI: 10.1055/s-0038-1626880

Original Article

Schattauer GmbH

Klinische Bedeutung der mit klassischen und atypischen Neuroleptika induzierten Hyperprolaktinämie

On conventional and atypical antipsychotics induced hyperprolactinaemia

L. Hermle

¹Klinik für Psychiatrie und Psychotherapie, Christophsbad (Chefarzt: Priv.-Doz. Dr. med. L. Hermle)

,

A. Bönsch

¹Klinik für Psychiatrie und Psychotherapie, Christophsbad (Chefarzt: Priv.-Doz. Dr. med. L. Hermle)

,

M. Ruchsow

¹Klinik für Psychiatrie und Psychotherapie, Christophsbad (Chefarzt: Priv.-Doz. Dr. med. L. Hermle)

› Author Affiliations

Abstract

Zusammenfassung

Die Behandlung mit atypischen Neuroleptika kann wie bei den klassischen Neuroleptika zu einer Hyperprolaktinämie führen. Diese bleibt in vielen klinischen Fällen zwar symptomlos, dennoch werden mit ihr neben dem Einfluss auf die Sexualfunktionen eine Vielzahl gesundheitlicher Folgewirkungen in Verbindung gebracht.

Summary

Like conventional neuroleptics, treatment with atypical antipsychotics may lead to side effects such as hyperprolactinemia. This side effect is associated with high prolactin levels and in many clinical cases does not show relevant symptoms. However, the impact of elevated prolactin levels on sexual functions and other sequels consequences has been subject of controversy.

Schlüsselwörter

Hyperprolaktinämie - atypische Neuroleptika - Risperidon

Keywords

Hyperprolactinemia - atypical antipsychotics - risperidone

Full Text

References

Literatur
1 Findling RL, Kusumakar V, Daneman D, DeSmedt CG Binder. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003; 64: 1362-9.
2 Haddad PM, Hellewell JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001; 15 (04) 293-5.
3 Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer?. Am J Psychiatry 1996; 153: 559-60.
4 Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J of Psychiatric Practice 2003; 09: 344-53.
5 Hamner MB, Arvanitis LA, Miller BG, Link CG, Hong WW. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636). Psychopharmacol Bull 1996; 32 (01) 107-10.
6 Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management. CNS Drugs 1998; 10 (03) 209-22.
7 Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002; Sep 14 (03) 163-73.
8 Kleinberg DL, Davis JM, deCoster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57-61.
9 Laakmann G. Psychopharmakoendokrinologie und Depressionsforschung. Berlin, Heidelberg: Springer; 1987
10 Maguire GA. Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 suppl 4 56-62.
11 Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607-18.
12 Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 1994; 12: 185-94.
13 Naber D, Ackenheil M, Laakmann G. Basal and stimulated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: relations to psychopathology. Adv Biochem Psychopharmacol 1980; 24: 419-23.
14 Pozo del E, Lancranjan I. Clinical use of drugs modifying the release of anterior pituitary hormones. In: Ganong WF, Martini L. (eds) Frontiers in neuroendocrinology. vol. 5. Elsevier; New York: 1978: 207-47.
15 Rjosk HK, Fahlbusch R, von Werder K. Spontaneous development of hyperprolactin-aemia. Acta Endocrinol (Copenh) 1982; 100: 333-6.
16 Rjosk HK, Fahlbusch R, Werder K. von. Influence of pregnancies on prolactinomas. Acta Endocrinol (Copenh) 1982; 100: 337-46.
17 Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Postel-Vinay MC, Trivin C, Kuttenn F, Kelly PA. Increased expression of prolactin receptor gene assessed by quantiative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998; 83 (02) 667-74.
18 Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
19 Werder K. von. Klinische Neuroendokrinologie. Berlin, Heidelberg: Springer Verlag; 1998
20 Werder K. von. Prolactinoma: Clinical findings and endocrinology. In: Landolt AM, Vance ML, Reilly PL. (eds.) Churchill-Livingstone, New York, London: Pituitary Adenomas; 1999
21 Zhang XY, Zhou DF, Shen YC. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology 2005; 178: 35-40.
22 Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiologie, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182: 199-204.
23 Wirz-Justice A, Pühringer W, Lacoste V, Graw P, Gastpar M. Intravenous L-5-hydroxy-tryptophan in normal subjects: an interdisciplinary precursor loading study. Pharmacopsychiatria 1976; 09: 277-88.